Stay updated on Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Sign up to get notified when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.

Latest updates to the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA 403 Forbidden error page is now displayed, replacing the study content with an access-denied message. The header and footer suggest a site-wide access restriction rather than study information.SummaryDifference19%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now shows Revision: v3.6.6, replacing the previous Revision: v3.6.5. This indicates a minor software/documentation version update rather than a change to the study details.SummaryDifference0.0%

- Check41 days agoChange DetectedA funding disclosure line reading '2015 ( U.S. NIH Grant/Contract )' was added, providing attribution for NIH support within the study's documentation. The addition clarifies the source of funding associated with the U.S. portion of the trial.SummaryDifference0.0%

- Check55 days agoChange DetectedThe page's revision was updated to v3.6.5 and the previous v3.6.4 was removed, reflecting a small metadata update to the revision history.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision: v3.6.4 is now shown, replacing the previous Revision: v3.6.3. This indicates a new page revision.SummaryDifference0.0%

- Check91 days agoChange DetectedThe page revision metadata was updated from v3.6.2 to v3.6.3, reflecting a newer version of the page.SummaryDifference0.0%

Stay in the know with updates to Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.